To characterize VGL101 as a high-affinity human TREM2 (hTREM2) agonistic monoclonal antibody and determine its capacity as a potential compensatory pharmacological approach to therapeutically circumvent colony-stimulating factor-1 receptor (CSF1R) dysfunction, which underlies the pathophysiology of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
No takes yet. Share an insight, caveat, or question.
Larson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: